CN117925484A - Lactobacillus reuteri JYLB-101 for improving sleep apnea, and product and application thereof - Google Patents
Lactobacillus reuteri JYLB-101 for improving sleep apnea, and product and application thereof Download PDFInfo
- Publication number
- CN117925484A CN117925484A CN202410309693.6A CN202410309693A CN117925484A CN 117925484 A CN117925484 A CN 117925484A CN 202410309693 A CN202410309693 A CN 202410309693A CN 117925484 A CN117925484 A CN 117925484A
- Authority
- CN
- China
- Prior art keywords
- jylb
- lactobacillus reuteri
- sleep apnea
- bacterial
- reuteri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186604 Lactobacillus reuteri Species 0.000 title claims abstract description 28
- 229940001882 lactobacillus reuteri Drugs 0.000 title claims abstract description 28
- 201000002859 sleep apnea Diseases 0.000 title claims abstract description 18
- 230000005800 cardiovascular problem Effects 0.000 claims abstract description 7
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 238000009629 microbiological culture Methods 0.000 claims abstract description 5
- 230000001580 bacterial effect Effects 0.000 claims description 28
- 239000000843 powder Substances 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 206010021143 Hypoxia Diseases 0.000 claims description 12
- 230000007954 hypoxia Effects 0.000 claims description 12
- 239000002068 microbial inoculum Substances 0.000 claims description 12
- 208000008784 apnea Diseases 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 10
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 10
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 239000005913 Maltodextrin Substances 0.000 claims description 7
- 229920002774 Maltodextrin Polymers 0.000 claims description 7
- 229940035034 maltodextrin Drugs 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 230000002107 myocardial effect Effects 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 235000020183 skimmed milk Nutrition 0.000 claims description 3
- 206010067775 Upper airway obstruction Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 17
- 238000011282 treatment Methods 0.000 abstract description 10
- 244000005700 microbiome Species 0.000 abstract description 3
- 230000036407 pain Effects 0.000 abstract description 3
- 239000006041 probiotic Substances 0.000 abstract description 2
- 235000018291 probiotics Nutrition 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 55
- 238000002474 experimental method Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 102000004420 Creatine Kinase Human genes 0.000 description 9
- 108010042126 Creatine kinase Proteins 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 238000005259 measurement Methods 0.000 description 8
- 208000001797 obstructive sleep apnea Diseases 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 6
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000000884 Airway Obstruction Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010044467 Isoenzymes Proteins 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- HTKLCTLNLJFVLN-UHFFFAOYSA-L P(=O)([O-])([O-])O.[K+].[K+].O.O.O.O.O.O.O Chemical compound P(=O)([O-])([O-])O.[K+].[K+].O.O.O.O.O.O.O HTKLCTLNLJFVLN-UHFFFAOYSA-L 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 3
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 3
- CDUFCUKTJFSWPL-UHFFFAOYSA-L manganese(II) sulfate tetrahydrate Chemical compound O.O.O.O.[Mn+2].[O-]S([O-])(=O)=O CDUFCUKTJFSWPL-UHFFFAOYSA-L 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 3
- 239000001393 triammonium citrate Substances 0.000 description 3
- 235000011046 triammonium citrate Nutrition 0.000 description 3
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000003254 palate Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ZDLZKMDMBBMJLI-FDMDGMSGSA-N 2-[[2-[[(2s)-2-[[(e)-3-(furan-2-yl)prop-2-enoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]acetic acid Chemical compound C([C@@H](C(=O)NCC(=O)NCC(=O)O)NC(=O)\C=C\C=1OC=CC=1)C1=CC=CC=C1 ZDLZKMDMBBMJLI-FDMDGMSGSA-N 0.000 description 1
- 108010048632 2-furanacryloyl-phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000010798 Tongue disease Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000012696 congenital leptin deficiency Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001847 jaw Anatomy 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 230000008065 myocardial cell damage Effects 0.000 description 1
- 210000000492 nasalseptum Anatomy 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 208000012802 recumbency Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000001738 temporomandibular joint Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of probiotics, in particular to lactobacillus reuteri JYLB-101 for improving sleep apnea, and a product and application thereof. Lactobacillus reuteri (Limosilactobacillus reuteri) JYLB-101 is preserved in China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) on 3/30 th year 2023, and the preservation address is No. 3 of West Song No. 1 of North Star of the Korean area of Beijing city, and the preservation number is CGMCC No.26790. The lactobacillus reuteri provided by the invention can relieve pain and side effects of sleep apnea treatment, and can help to improve cardiovascular problems caused by sleep apnea after administration.
Description
Technical Field
The invention relates to the technical field of probiotics, in particular to lactobacillus reuteri JYLB-101 for improving sleep apnea, and a product and application thereof.
Background
Obstructive sleep apnea-hypopnea syndrome (OSAHS) is a sleep respiratory disorder with clinical manifestations of nocturnal snoring with apnea, daytime sleepiness, listlessness, hypomnesis. The repeated night hypoxia and hypercarbonated blood diseases caused by the apnea can lead to complications such as hypertension, coronary heart disease, diabetes, cerebrovascular diseases and traffic accidents, and even night sudden death. OSAHS is therefore a potentially fatal sleep respiratory disorder.
The direct pathogenesis of OSAHS is stenosis and obstruction of the upper airway, but its onset is not simple airway obstruction, actually upper airway collapse, with a disturbance in respiratory central nervous regulator. The upper airway stenosis and obstruction are caused by a plurality of reasons, including nasal septum bending, tonsil hypertrophy, overlong soft palate, mandibular arch stenosis, mandibular retrogressive deformity, temporomandibular joint rigidity, small jaw deformity which is secondary to bilateral joint rigidity and occurs in a few cases, giant tongue diseases, retroglossial glossoside and the like. In addition, obesity, mucous edema of upper airway tissues, and tumors of the oropharynx or hypopharynx can all cause OSAHS.
The treatment of OSAHS is divided into non-operative treatment and operative treatment, except weight loss of patients with lateral recumbency, smoking cessation wine and obesity. Non-operative treatments include nasal continuous positive airway pressure breathing, which generally achieve better therapeutic results, and oral appliances, which generally have significant effects on serious conditions. The purpose of surgical treatment is to alleviate and eliminate airway obstruction and prevent collapse of airway soft tissue. The choice of which procedure is based on the location of the airway obstruction, the severity of the obstruction, whether morbid obesity is present, and the general condition. Surgical treatment generally causes a certain amount of trauma and pain during the treatment process can also lead to patient conflict with the surgical treatment unless it is already very serious. At the same time, cardiovascular diseases caused by OSAHS are difficult to recover after the treatment mode is finished or take a long time to recover, and the side effects of the drugs are caused by drug treatment.
Disclosure of Invention
Aiming at the technical problems that skin wounds are difficult to heal and side effects exist in medicines in the existing OSAHS treatment method, the invention provides lactobacillus reuteri JYLB-101 for improving sleep apnea, and products and applications thereof, so that pain and side effects of the sleep apnea treatment are relieved, and cardiovascular problems caused by the sleep apnea can be improved in an auxiliary way after the administration.
In a first aspect, the present invention provides lactobacillus reuteri (Limosilactobacillus reuteri) JYLB-101 for improving sleep apnea, which has been deposited in China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) for 3 months 2023, wherein the deposited address is the Seagaku No.1, 3 in the Chaoyang area North Star in Beijing, and the deposited number is CGMCC No.26790.
In a second aspect, the invention also provides an application of the lactobacillus reuteri JYLB-101 in preparing the bacterial powder for improving sleep apnea.
Further, the preparation method of the fungus powder comprises washing lactobacillus reuteri JYLB-101 thallus with sterile physiological saline, re-suspending in reconstituted skim milk, freeze drying, and pulverizing.
Further, inoculating activated lactobacillus reuteri JYLB-101 into MRS liquid culture medium, culturing at 37 ℃ for 24 hours to obtain bacterial liquid, and centrifuging the bacterial liquid to obtain the bacterial body.
Further, the concentration of Lactobacillus reuteri JYLB-101 in the bacterial suspension is 1.0-2.0X10- 10 cfu/mL.
Furthermore, the bacterial powder for improving sleep apnea can inhibit angiotensin converting enzyme, reduce the number of times of apnea, improve blood oxygen saturation, relieve anxiety state caused by upper respiratory tract obstruction, improve cardiovascular problem caused by intermittent hypoxia and regulate myocardial enzyme level.
In a third aspect, the invention also provides a microbial inoculum, which comprises bacterial powder prepared by adopting the lactobacillus reuteri JYLB-101 and maltodextrin.
Further, the amount of lactobacillus reuteri JYLB-101 powder in the microbial inoculum is 1.0X10- 9 cfu/g.
The invention has the beneficial effects that:
Experiments on rats prove that the lactobacillus reuteri JYLB-101 strain screened by the invention has the capability of assisting in improving mental and cardiovascular problems caused by sleep apnea.
Detailed Description
In order to make the technical solution of the present invention better understood by those skilled in the art, the technical solution of the present invention will be clearly and completely described in the following in conjunction with the embodiments of the present invention, and it is obvious that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the present invention without making any inventive effort, shall fall within the scope of the present invention.
Example 1 isolation, screening and identification of species
1. Strain screening and purification
(1) Sampling: 2022, 3 months, was taken from the old people in century, qing, shandong, cold chain transported back to laboratory for sample preparation;
(2) Preparing a sample: ① Adding 1g of the sample obtained in the step (1) into an conical flask containing sterile normal saline, stirring and oscillating for 30min at 4 ℃ for later use; ② Diluting the solution obtained in the step ① to prepare samples with different concentration gradients, namely 10 -1、10-2、10-3、10-4、10-5、10-6、10-7 respectively for later use;
(3) MRS plate medium containing 0.5% CaCO 3 was prepared: weighing 10g of peptone, 5g of beef powder, 5g of sodium acetate trihydrate, 2g of dipotassium phosphate heptahydrate, 1mL of Tween 80, 0.05g of manganese sulfate tetrahydrate, 2g of triammonium citrate, 20g of glucose, 0.2g of magnesium sulfate heptahydrate, 5g of calcium carbonate, 15g of agar and 1000mL of distilled water; mixing the above materials, adjusting pH to 6.8, heating, mixing, and sterilizing at 121deg.C and 0.1MPa for 20 min; pouring the sterilized culture medium into a plate, and cooling for later use;
(4) Culturing: coating the solutions with different dilution concentrations in the step ② on a solid culture medium by using a coating rod respectively, and culturing for 48 hours at 37 ℃ under anaerobic conditions;
(5) Selecting bacterial colonies: colonies were selected according to the following colony characteristics:
The diameter is 1-2mm, the colony is round, the edge is neat, the middle of the micro white is provided with a bulge, and the calcium dissolving ring is larger.
(6) And (3) separating and purifying: and (3) according to the appearance form judgment, 46 single colonies are selected from the colony characteristics in the step (5), inoculated on the culture medium in the step (3) by a streaking method, cultured for 48 hours at 37 ℃ under anaerobic conditions, the operation is repeated for 2-3 times, the single colonies are selected, and the single colonies are placed in a glycerol tube for preservation at the temperature of minus 70 ℃ to serve as an alternative strain.
2. Screening of Angiotensin Converting Enzyme (ACE) inhibiting strains
Angiotensin Converting Enzyme (ACE) converts angiotensin I to angiotensin II, which causes severe vasoconstriction. By inhibiting ACE, the vasoconstriction is relieved, and the blood pressure is reduced. ACE can catalyze FAPGG to decompose into FAP and GG, inhibiting ACE activity can reduce the decomposition, and the inhibition rate is calculated.
(1) Preparation of bacterial liquid
Culturing 46 separated strains by adopting a streaking method, respectively picking a single colony of an inoculating loop, inoculating the single colony into a liquid culture medium, and culturing for 24 hours at 37 ℃ for later use.
The preparation method of the liquid culture medium comprises the following steps:
Weighing 10g of peptone, 5g of beef powder, 5g of sodium acetate trihydrate, 2g of dipotassium phosphate heptahydrate, 1mL of Tween 80, 0.05g of manganese sulfate tetrahydrate, 2g of triammonium citrate, 20g of glucose, 0.2g of magnesium sulfate heptahydrate and 1000mL of distilled water; mixing the above materials, adjusting pH to 6.8, heating, mixing, and sterilizing at 121deg.C under 0.1MPa for 20min.
(2) Sample preparation
An angiotensin converting enzyme inhibitor activity detection kit (Beijing Soy bao) was prepared, 0.1mL of fermentation broth prepared from 46 different strains was taken respectively, 1mL of the reagent in the kit was added, and the mixture was subjected to ice bath ultrasonic disruption (power 200W, ultrasonic disruption for 3 seconds, interval of 7 seconds, total time of 5 minutes). After the completion, 12000g is centrifuged for 20min at 4 ℃, and the supernatant is taken and placed on ice for testing.
(3) Detection of ACE Activity inhibiting Strain
The loading procedure in a 1mL quartz cuvette is shown in Table 1 below:
TABLE 1 sample addition step
Mixing thoroughly, measuring absorbance A1 at 340nm for 10s, rapidly standing at 37deg.C for 30min, measuring absorbance A2 at 30min and 10s, respectively denoted as A1 Blank space 1、A1 Blank space 2、A1 Measurement 、A1 Positive and negative and A2 Blank space 1、A2 Blank space 2、A2 Measurement 、A2 Positive and negative , calculating ΔA Blank space =（A1 Blank space 1-A2 Blank space 1）-（A1 Blank space 2-A2 Blank space 2）,ΔA Measurement =A1 Measurement -A2 Measurement ,ΔA Positive and negative =A1 Positive and negative -A2 Positive and negative .
Angiotensin converting enzyme inhibitor activity calculation:
ACE inhibitor inhibition (%) = (Δa Blank space -ΔA Measurement ）÷ΔA Blank space ×100%.
(4) Detection result
Among 46 strains, 3 strains had an inhibition rate of more than 50%, wherein the highest inhibition rate was 82.2%, designated JYLB-101, and the other two strains were designated JYL4-072 and JYL9-119, respectively, with inhibition rates of 59.3% and 67.8% in this order.
3. Authentication and preservation
Strains JYLB-101 were sent to the identification unit: the primers used in the identification process of the biological engineering (Shanghai) Co., ltd were as follows:
27F：5'-AGAGTTTGATCCTGGCTCAG-3'；
1492R：5'-GGTTACCTTGTTACGACTT-3'。
this strain was identified as Limosilactobacillus reuteri (lactobacillus reuteri).
The gene sequence of the lactobacillus reuteri (Limosilactobacillus reuteri) JYLB-101 is as follows:
CCATAAAGGTTAGGCCACCGACTTTGGGCGTTACAAACTCCCATGGTGTGACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCGGCATGCTGATCCGCGATTACTAGCGATTCCGACTTCGTGTAGGCGAGTTGCAGCCTACAGTCCGAACTGAGAACGGCTTTAAGAGATTAGCTTACTCTCGCGAGTTTGCGACTCGTTGTACCGTCCATTGTAGCACGTGTGTAGCCCAGGTCATAAGGGGCATGATGATCTGACGTCGTCCCCACCTTCCTCCGGTTTGTCACCGGCAGTCTCACTAGAGTGCCCAACTTAATGCTGGCAACTAGTAACAAGGGTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACGACCATGCACCACCTGTCATTGCGTCCCCGAAGGGAACGCCTTATCTCTAAGGTTAGCGCAAGATGTCAAGACCTGGTAAGGTTCTTCGCGTAGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGCCCCCGTCAATTCCTTTGAGTTTCAACCTTGCGGTCGTACTCCCCAGGCGGAGTGCTTAATGCGTTAGCTCCGGCACTGAAGGGCGGAAACCCTCCAACACCTAGCACTCATCGTTTACGGCATGGACTACCAGGGTATCTAATCCTGTTCGCTACCCATGCTTTCGAGCCTCAGCGTCAGTTGCAGACCAGACAGCCGCCTTCGCCACTGGTGTTCTTCCATATATCTACGCATTCCACCGCTACACATGGAGTTCCACTGTCCTCTTCTGCACTCAAGTCGCCCGGTTTCCGATGCACTTCTTCGGTTAAGCCGAAGGCTTTCACATCAGACCTAAGCAACCGCCTGCGCTCGCTTTACGCCCAATAAATCCGGATAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACGTAGTTAGCCGTGACTTTCTGGTTGGATACCGTCACTGCGTGAACAGTTACTCTCACGCACGTTCTTCTCCAACAACAGAGCTTTACGAGCCGAAACCCTTCTTCACTCACGCGGTGTTGCTCCATCAGGCTTGCGCCCATTGTGGAAGATTCCCTACTGCTGCCTCCCGTAGGAGTATGGACCGTGTCTCAGTTCCATTGTGGCCGATCAGTCTCTCAACTCGGCTATGCATCATCGCCTTGGTAAGCCGTTACCTTACCAACTAGCTAATGCACCGCAGGTCCATCCCAGAGTGATAGCCAAAGCCATCTTTCAAACAAAAGCCATGTGGCTTTTGTTGTTATGCGGTATTAGCATCTGTTTCCAAATGTTATCCCCCGCTCCGGGGCAGGTTACCTACGTGTTACTCACCCGTCCGCCACTCACTGGTGATCCATCGTCAATCAGGTGCAAGCACCATCAATCAGTTGGGCCAGTGCGT.
Lactobacillus reuteri (Limosilactobacillus reuteri) JYLB-101 is delivered to China general microbiological culture Collection center for culture Collection of microorganisms (CGMCC No. 26790) at 2023 and 3 months.
EXAMPLE 2 preparation of microbial inoculum
1. The fermentation process of the fungus powder comprises the following steps:
Mixing 10g of peptone, 5g of beef extract powder, 5g of sodium acetate trihydrate, 2g of dipotassium phosphate heptahydrate, 1mL of Tween 80, 0.05g of manganese sulfate tetrahydrate, 2g of triammonium citrate, 20g of glucose, 0.2g of magnesium sulfate heptahydrate and 1000mL of distilled water, regulating the pH value to 6.8, heating and uniformly mixing, and sterilizing at 121 ℃ and 0.1MPa for 20min to obtain an MRS liquid culture medium;
Taking JYLB-101, JYL4-072 and JYL9-119 screened in the example 1, activating the products on an MRS flat plate culture medium of 0.5% CaCO 3 (the preparation method is the same as that in the example 1), inoculating activated bacteria into an MRS liquid culture medium according to the inoculum size of 1% (w/w), and then culturing for 24 hours at 37 ℃ to obtain bacterial liquid;
centrifuging the bacterial liquid, collecting bacterial cells, washing the bacterial cells by using sterile physiological saline, and then, re-suspending the bacterial cells in 15% (w/w) reconstituted skim milk to obtain suspension; the concentration of the suspension is regulated to be 1.0-2.0X10 10 cfu/mL to obtain bacterial suspension, the bacterial suspension is frozen and dried and crushed, and the bacterial suspension is mixed with maltodextrin (purchased from Bolborona biological Co., ltd.) to prepare the bacterial preparation.
In this example, the number of cells in each of the three bacterial preparations was 1.0X10 9 cfu/g.
EXAMPLE 3 improvement of the upper airway obstruction rats by Lactobacillus reuteri JYLB-101
1. Rat grouping
SPF-class SD rats (purchased from Australian corporation of Beijing) were 70, 6 weeks old, and had a body weight of 203 g.+ -.11 g, 12 were randomly selected as control groups, and the remaining 58 were subjected to modeling. The molding process is as follows:
the rat is anesthetized by intraperitoneal injection of 2% pentobarbital sodium, then the oral cavity of the rat is fixed and opened by an opening device, the pharyngeal cavity is exposed, the medical sodium hyaluronate is injected into a plurality of places such as lingual palate arch (bilateral), pharyngeal palate arch, tongue root and the like in the oral cavity until visible protrusion exists, and the operation process avoids the choking death of the rat. Whether modeling was successful required detection of the following indicators by vital sign monitors (STARR company, usa):
The stopping time of the oral-nasal airflow is longer than 10s; the oral-nasal airflow intensity is lower than 50% of the normal rat airflow intensity; blood oxygen saturation was reduced by more than 3% compared to normal rats; with a slight arousal; when the number of times of apnea and the low ventilation index (AHI) are not less than 5 times/h, the molding is successfully performed.
Of these 48 rats successfully modeled were selected and randomly divided into four groups. The previous 12 rats were added as control groups and the experiment was performed in 5 groups. The specific operation is as follows:
control group: normal rats were gavaged with 0.02g maltodextrin per day for 4 weeks as a control.
Model group: 12 rats were successfully molded, and 0.02g maltodextrin per day was infused with stomach as a control for 4 weeks.
JYLB-101 groups: 12 rats were successfully molded, and 0.02g JYLB-101 microbial inoculum was infused daily for 4 weeks.
JYL4-072 group: 12 rats were successfully molded, and 0.02g of JYL4-072 microbial inoculum was infused daily for 4 weeks.
JYL9-119 group: 12 rats were successfully molded, and 0.02g of JYL9-119 strain was infused daily for 4 weeks.
2. Comparison of apnoea times
After 4 weeks of experiment, the respiratory rate and respiratory amplitude of 5 groups of rats are detected by using a vital sign monitor, the number of times of apnea is counted, and if the respiratory waveform displayed by the instrument continuously disappears for 2.5s, the respiratory waveform is one time. A total of 2h were counted. The statistical results are shown in table 2:
Table 2 rat apnea count (n=12, count x±s)
* P < 0.05 compared to control; # in comparison to model group, p < 0.05.
As can be seen from table 2, the control group had significantly fewer apneas than the other groups, but the JYLB-101 groups had significantly fewer apneas than the model group. The JYLB-101 microbial inoculum has a certain improvement effect on the problem of rat apnea.
3. Oxygen saturation contrast
After 4 weeks of experiment, the average blood oxygen saturation and the minimum blood oxygen saturation of 5 groups of rats were detected for 2 hours using a vital sign monitor. The statistical results are shown in table 3:
table 3 blood oxygen saturation of rats (n=12,%, x±s)
* P < 0.05 compared to control; # in comparison to model group, p < 0.05.
As can be seen from Table 3, the control group showed significantly higher blood oxygen saturation than the other groups, and the JYLB-101 groups showed significantly higher blood oxygen saturation than the model group. The JYLB-101 microbial inoculum has a certain improvement effect on the blood oxygen saturation of rats.
4. Open field experiment
After 4 weeks of experiment, each group of rats was subjected to open field experiments in a darkened, constant temperature, quiet room. The field of 60cm (length) ×60cm (width) ×40cm (height) was divided into 25 lattices at the computer analysis system side using an animal behavior recording analyzer. The total course of the mice in open field activity and the central grid dead time (central 9 grids) course were recorded for 10min (see table 4).
Table 4 results of the rat open field experiment (n=12, x.+ -. S)
* P < 0.05 compared to control; # in comparison to model group, p < 0.05.
As can be seen from table 4, the model rats had significantly more course of action than the control but a shorter retention time in the central square, indicating that the model rats were in anxiety. Compared with the model group, the total distance of JYLB-101 groups of rats is obviously shortened, the retention time of the central square lattice is obviously prolonged, and the JYLB-101 bacterial agent has an effect of improving the anxiety state of the rats caused by upper respiratory tract obstruction.
Example 4 effect of Lactobacillus reuteri JYLB-101 on improving cardiovascular problems in rats caused by intermittent hypoxia
1. Rat grouping
SPF-class SD rats (purchased from Australian corporation of Beijing) were 60 animals 7 weeks old, 219 g.+ -. 12g, 10 animals were randomly selected as control groups, and the remaining 50 animals were subjected to modeling. The molding process is as follows:
Rats were placed in a hypoxia chamber (Shanghai Jade scientific instruments Co., ltd.) that was subjected to 12h/12h dimming alternation to simulate daytime and nighttime. Intermittent hypoxia simulation was performed for 8 hours in the middle of the night phase, and the simulation process was: the oxygen concentration was reduced from 21% to 9% for 40s over a period of 50s and then increased from 9% to 21% for 40s over a period of 50 s. This process was a cycle for a total of 3 minutes. This was done 8 hours per day for 4 weeks.
40 Of the model rats were selected and randomly divided into four groups. The previous 10 rats were added as control groups and the experiment was performed in 5 groups. The specific operation is as follows:
control group: normal rats were perfused with 0.02g maltodextrin per day for 4 weeks as a control.
Model group: for the rats to be molded, the rats were fed with maltodextrin at 0.02g per day for 4 weeks as a control after 30min before being fed into the hypoxia chamber.
JYLB-101 groups: for the rats to be molded, the rats are filled with the microbial inoculum of 0.02g JYLB-101 for 4 weeks 30min before being fed into the hypoxia chamber each day.
JYL4-072 group: for the rats to be molded, the rats were fed with JYL4-072 inoculum at a rate of 0.02g for 4 weeks 30min before being fed into the hypoxia chamber.
JYL9-119 group: for the rats to be molded, the rats were fed with JYL9-119 strain for a period of 4 weeks after 30min before being fed into the hypoxia chamber.
2. Comparison of blood pressure changes
Blood pressure before and after 4 weeks of the experiment was measured, rat tail arterial blood pressure was detected using a rat noninvasive sphygmomanometer, and the rats were required to be measured in a quiet state, and average was taken three times per continuous measurement. The measurement results are shown in table 5:
Table 5 rat blood pressure control (n=10, mmHg, x.+ -. S)
* P < 0.05 compared to control; # in comparison to model group, p < 0.05.
As can be seen from table 5, there was no significant difference in blood pressure between the groups of rats prior to the experiment. The blood pressure of the model group is obviously higher than that of the control group after the experiment is finished, which indicates that the modeling process has obvious influence on the blood pressure of rats. After the experiment is finished, JYLB-101 groups have obvious differences compared with the model groups, which shows that the JYLB-101 microbial inoculum has a certain effect of improving the cardiovascular problems of rats caused by intermittent hypoxia.
3. Myocardial enzyme variation contrast
When the heart is damaged, myocardial enzymes including Creatine Kinase (CK), creatine kinase isozymes (CK-MB), lactate Dehydrogenase (LDH) in myocardial cells leak into the blood, resulting in an increase in the content of the three enzymes in serum. By detecting the contents of the three enzymes, it can be judged whether the myocardial cells are damaged.
Before the rats were bled, they were fasted for 12h, after which 20% (w/w) of uratam was injected at a rate of 0.5mL/100g of rat body weight for anesthesia and abdominal aortic blood collection. The blood sample was centrifuged at 1500g at 4℃for 15min, and the supernatant was collected and stored at-80 ℃. The serum was assayed for Creatine Kinase (CK), creatine kinase isozymes (CK-MB), lactate Dehydrogenase (LDH) content using a fully automatic blood analyzer (HORIBA, france). The test results are shown in Table 6:
table 6 rat blood pressure control (n=10, U/L, x.+ -. S)
* P < 0.05 compared to control; # in comparison to model group, p < 0.05.
As can be seen from table 6, the amounts of Creatine Kinase (CK), creatine kinase isoenzyme (CK-MB) and Lactate Dehydrogenase (LDH) in the model group after the experiment was completed were significantly higher than those in the control group, indicating that the modeling process had a significant effect on blood pressure in rats. After the experiment is finished, JYLB-101 groups have obvious differences compared with the model groups, which shows that the JYLB-101 microbial inoculum has a certain protection effect on the problem of rat myocardial cell injury caused by intermittent hypoxia.
Although the present invention has been described in detail by way of preferred embodiments, the present invention is not limited thereto. Various equivalent modifications and substitutions may be made in the embodiments of the present invention by those skilled in the art without departing from the spirit and scope of the present invention, and it is intended that all such modifications and substitutions be within the scope of the present invention/be within the scope of the present invention as defined by the appended claims.
Claims (8)
1. Lactobacillus reuteri (Limosilactobacillus reuteri) JYLB-101 for improving sleep apnea is characterized in that the lactobacillus reuteri is preserved in China general microbiological culture Collection center (China general microbiological culture Collection center) for 3 months in 2023, and the preservation address is the No. 3 of the West-1 hospital of North Star in the Korean area of Beijing city, and the preservation number is CGMCC No.26790.
2. Use of lactobacillus reuteri JYLB-101 as defined in claim 1 for the preparation of a powder for improving sleep apnea.
3. The use according to claim 2, wherein the preparation method of the bacterial powder for improving sleep apnea is that lactobacillus reuteri JYLB-101 bacterial cells are washed by sterile physiological saline, resuspended in reconstituted skim milk to obtain bacterial suspension, freeze-dried and crushed.
4. The use according to claim 3, wherein the activated lactobacillus reuteri JYLB-101 is inoculated in MRS liquid medium, cultured for 24 hours at 37 ℃ to obtain bacterial liquid, and the bacterial liquid is centrifuged to obtain bacterial cells.
5. The use according to claim 3, wherein the concentration of lactobacillus reuteri JYLB-101 in the bacterial suspension is 1.0-2.0x10 10 cfu/mL.
6. The use according to claim 2, wherein the sleep apnea improving bacterial powder inhibits angiotensin converting enzyme, reduces the number of apneas, improves blood oxygen saturation, relieves anxiety due to upper airway obstruction, improves cardiovascular problems due to intermittent hypoxia and regulates myocardial enzyme levels.
7. A microbial agent comprising a microbial powder prepared by lactobacillus reuteri JYLB-101 according to claim 1 and maltodextrin.
8. The microbial inoculum of claim 7, wherein the amount of lactobacillus reuteri JYLB-101 powder in the microbial inoculum is 1.0x10 9 cfu/g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410309693.6A CN117925484B (en) | 2024-03-19 | Lactobacillus reuteri JYLB-101 for improving sleep apnea, and product and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410309693.6A CN117925484B (en) | 2024-03-19 | Lactobacillus reuteri JYLB-101 for improving sleep apnea, and product and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117925484A true CN117925484A (en) | 2024-04-26 |
| CN117925484B CN117925484B (en) | 2024-07-09 |
Family
ID=
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020037577A1 (en) * | 2000-05-17 | 2002-03-28 | Park Han Oh | Microorganisms for treatment or prevention of corpulence and diabetes mellitus, and pharmaceutical composition containing the same |
| JP2004073178A (en) * | 2002-08-09 | 2004-03-11 | Bioneer Corp | Microorganism for preventing/treatment of obesity and diabetes mellitus |
| US20040071680A1 (en) * | 2002-08-09 | 2004-04-15 | Song Su Han | Microorganisms which are taken effects in preventing and/or treating obesity or diabetes mellitus |
| JP2006290835A (en) * | 2005-04-14 | 2006-10-26 | Mitsukan Group Honsha:Kk | Functional composition exhibiting ace inhibitory activity and having hypotensive activity |
| US20070280913A1 (en) * | 2006-06-05 | 2007-12-06 | Eamonn Connolly | Use of selected lactic acid bacteria for reducing infantile colic |
| CN101541947A (en) * | 2006-08-04 | 2009-09-23 | 株式会社百奥尼 | Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation |
| CN112430553A (en) * | 2020-11-25 | 2021-03-02 | 山东向日葵生物工程有限公司 | Lactobacillus reuteri SF-L-25 with helicobacter pylori inhibiting function and application thereof |
| CN113430153A (en) * | 2021-08-10 | 2021-09-24 | 浙江大学 | Lactobacillus reuteri ZJuuds 09 for reducing blood pressure and application thereof |
| CN113943687A (en) * | 2021-12-21 | 2022-01-18 | 山东中科嘉亿生物工程有限公司 | Lactobacillus reuteri JYLB-291 for improving ulcerative colitis and application thereof |
| WO2022222259A1 (en) * | 2021-04-18 | 2022-10-27 | 青岛蔚蓝生物股份有限公司 | Lactobacillus reuteri having improved anti-aging and hair health enhancement effects, and application thereof |
| WO2022259230A1 (en) * | 2021-06-11 | 2022-12-15 | Probiotical S.P.A. | Strains of probiotic bacteria for use in a preventive method of treatment or in an adjuvant method of treatment of viral respiratory infections |
| CN117126789A (en) * | 2023-10-25 | 2023-11-28 | 山东中科嘉亿生物工程有限公司 | Lactobacillus reuteri JYLB-151 for preventing and treating pneumonia and application thereof |
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020037577A1 (en) * | 2000-05-17 | 2002-03-28 | Park Han Oh | Microorganisms for treatment or prevention of corpulence and diabetes mellitus, and pharmaceutical composition containing the same |
| JP2004073178A (en) * | 2002-08-09 | 2004-03-11 | Bioneer Corp | Microorganism for preventing/treatment of obesity and diabetes mellitus |
| US20040071680A1 (en) * | 2002-08-09 | 2004-04-15 | Song Su Han | Microorganisms which are taken effects in preventing and/or treating obesity or diabetes mellitus |
| JP2006290835A (en) * | 2005-04-14 | 2006-10-26 | Mitsukan Group Honsha:Kk | Functional composition exhibiting ace inhibitory activity and having hypotensive activity |
| US20070280913A1 (en) * | 2006-06-05 | 2007-12-06 | Eamonn Connolly | Use of selected lactic acid bacteria for reducing infantile colic |
| CN101541947A (en) * | 2006-08-04 | 2009-09-23 | 株式会社百奥尼 | Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation |
| CN112430553A (en) * | 2020-11-25 | 2021-03-02 | 山东向日葵生物工程有限公司 | Lactobacillus reuteri SF-L-25 with helicobacter pylori inhibiting function and application thereof |
| WO2022222259A1 (en) * | 2021-04-18 | 2022-10-27 | 青岛蔚蓝生物股份有限公司 | Lactobacillus reuteri having improved anti-aging and hair health enhancement effects, and application thereof |
| WO2022259230A1 (en) * | 2021-06-11 | 2022-12-15 | Probiotical S.P.A. | Strains of probiotic bacteria for use in a preventive method of treatment or in an adjuvant method of treatment of viral respiratory infections |
| CN113430153A (en) * | 2021-08-10 | 2021-09-24 | 浙江大学 | Lactobacillus reuteri ZJuuds 09 for reducing blood pressure and application thereof |
| CN113943687A (en) * | 2021-12-21 | 2022-01-18 | 山东中科嘉亿生物工程有限公司 | Lactobacillus reuteri JYLB-291 for improving ulcerative colitis and application thereof |
| CN117126789A (en) * | 2023-10-25 | 2023-11-28 | 山东中科嘉亿生物工程有限公司 | Lactobacillus reuteri JYLB-151 for preventing and treating pneumonia and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| BADRAN M等: "The gut microbiome as a target for adjuvant therapy in obstructive sleep apnea", EXPERT OPINION ON THERAPEUTIC TARGETS, vol. 24, no. 12, 1 August 2020 (2020-08-01), pages 1263 - 1282 * |
| 孙爱玲;裴敏青;刘德光;夏彩凤;段全纪;: "罗伊氏乳杆菌对轮状病毒感染肠炎患儿免疫功能与肠道菌群及临床疗效的影响", 中华医院感染学杂志, no. 07, 31 December 2020 (2020-12-31), pages 104 - 108 * |
| 宋佳等: "罗伊氏粘液乳杆菌HCS02-001 培养方法优化及改善睡眠功能 研究", 生物技术进展, vol. 14, no. 1, 25 January 2024 (2024-01-25), pages 133 - 140 * |
| 李军训;罗学刚;高洁;郝冉;张同存;: "益生菌的分类、生理功能与有效性评价研究进展", 中国农业科技导报, no. 06, 31 December 2010 (2010-12-31), pages 49 - 55 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107502575B (en) | Lactobacillus plantarum with high alpha-glucosidase inhibition activity | |
| CN106619743A (en) | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink | |
| CN108823125A (en) | A kind of production method and application for treating sleep disturbance probiotics preparation | |
| CN113197249B (en) | Yoghurt comprising lactobacillus paracasei Lc19 and preparation method and application thereof | |
| CN104415060A (en) | Edible composition as well as preparation method and application thereof | |
| CN111560331B (en) | Lactobacillus paracasei and application thereof | |
| CN113755409B (en) | Bifidobacterium longum for relieving insulin resistance and application thereof | |
| CN115607577B (en) | Probiotics with efficacy of relieving stomatitis, and preparation method and application thereof | |
| CN113969253B (en) | Bifidobacterium lactis JYBR-390 with constipation treatment effect and application and product thereof | |
| KR100404236B1 (en) | Microorganisms for Corpulence or Diabetes Mellitus, or a pharmaceutical composition containing the same | |
| CN115120646A (en) | Probiotic composition for balancing intestinal flora and preparation method and application thereof | |
| CN106309506B (en) | Probiotics composition with menstruation regulating function and application thereof | |
| CN117925484B (en) | Lactobacillus reuteri JYLB-101 for improving sleep apnea, and product and application thereof | |
| CN104605018A (en) | Functional fermented milk and preparation method thereof | |
| CN116855413B (en) | Bioactive substance for regulating human body microecological balance prepared from lactobacillus rhamnosus YSs069 and application thereof | |
| CN115895966B (en) | Bifidobacterium bifidum BL002 for assisting in relieving gout and application thereof | |
| CN117925484A (en) | Lactobacillus reuteri JYLB-101 for improving sleep apnea, and product and application thereof | |
| CN114836349B (en) | Lactobacillus acidophilus LA16 for antagonizing helicobacter pylori and application thereof | |
| TW201216866A (en) | Intestine immunomodulator | |
| CN113913330B (en) | Lactobacillus plantarum for regulating OVA-specific IgE and application thereof | |
| WO2004113509A1 (en) | Lactobacillus casei lc2w strain and its use in antihypertensive aspect | |
| CN109954000B (en) | Application of donkey milk in preparation of food or medicine, and food and medicine for treating ulcerative colitis | |
| TWI837529B (en) | Use of lactobacillus fermentum gkf3 for preparing oral composition of reducing tobacco addiction | |
| CN116656549B (en) | Probiotic capable of improving sleep quality and application thereof | |
| CN115109713B (en) | Probiotics and biological agents for alleviating traumatic oral lesions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |